Navigation Links
Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
Date:10/28/2010

SAN DIEGO, Oct. 28 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

"We are excited to begin our journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent.  Our first step is to understand the safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this compound in normal healthy subjects," said Isabelle DeArmond, Vice President, Clinical Development.  "We expect to have these studies completed by the middle of next year, and assuming positive results, we could then begin to study the therapeutic utility of AM152 in patients."

"The Amira team is very proud and excited by this important milestone," said Bob Baltera, Chief Executive Officer. "Currently, there are no FDA-approved therapies for fibrotic disease, and we look forward to better understanding the potential therapeutic benefit of an LPA1 antagonist in this area of medicine."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this as a target for novel treatment in various fibrotic diseases including scleroderma and idiopathic pulmonary fibrosis.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
2. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
3. Visage Imaging Releases Amira 5.3
4. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
5. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
6. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
7. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
8. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
9. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
10. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
11. Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals Antibody Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):